Bacterial News and Research

RSS

PolyMedix completes first two segments of its PMX-30063 antibiotic drug candidate Phase 1B study

PolyMedix, Inc., an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, has successfully completed the first two segments of a Phase 1B clinical safety study with its novel antibiotic drug candidate PMX-30063.

18 Dec 2009

Safe living guidelines for transplant recipients

Keeping pets healthy can reduce infection risks for people who have received solid organ transplants and veterinarians should be seen as an integral part of the healthcare team. That's just one of the key pieces of advice from a safe living article published in an infectious diseases supplement in the American Journal of Transplantation.

18 Dec 2009

Study explains Salmonella's infection strategy

Salmonella are highly adaptive bacteria. They can live in the presence and absence of oxygen and thus propagate in the gut. The ingestion by humans occurs mainly via contaminated egg dishes such as mayonnaise or raw milk products as well as meat or sausages. Infections with Salmonella lead to severe diarrhea and fever, particularly in patients harbouring a compromised immune system.

17 Dec 2009

Cannabis for Ulcerative Colitis and Crohn's Disease treatment

Chemicals found in cannabis could prove an effective treatment for the inflammatory bowel diseases Ulcerative Colitis and Crohn's Disease, say scientists.

17 Dec 2009

Wood pallet: A source of food poisoning bacteria

In a random sampling of wood pallets used to ship food in Portland, ME, and Philadelphia, PA, numerous pallets tested positive for Listeria and abnormally high counts of bacteria that could potentially create health hazards for consumers.

17 Dec 2009

New licensing agreement to develop and commercialize prophylactic vaccine against MRSA signed

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that it has entered into an exclusive, world-wide licensing agreement with Syntiron to develop and commercialize its prophylactic vaccine against Staphylococcus, including Methicillin-Resistant Staphylococcus aureus or MRSA.

17 Dec 2009

Survey examines disease R&D investment in 2008

According to an annual survey released Tuesday by the George Institute for International Health that looks at research and development (R&D) funding of diseases that affect the developing world, the U.S. government in 2008 "remained the single biggest contributor as it again provided almost half of the total funding but the report notes developing countries like Brazil [and] India ... were becoming a growing force," AAP/Sydney Morning Herald reports (Rose, 12/15).

17 Dec 2009

Scientists draw on bacterial decision-making success to guide human choices on H1N1 vaccine

Bacteria inhabited our planet for more than 4 billion years before humans showed up, and they'll probably outlive us by as many eons more. That suggests they may have something to teach us.

17 Dec 2009

Syntiron grants sanofi pasteur exclusive world-wide license to its human vaccine against MRSA

Syntiron today announced that it has granted sanofi pasteur an exclusive world-wide license to its human vaccine against Staphylococcus aureus. The agreement includes an undisclosed initial licensing fee, milestone payments and royalty payments on future sales of the product. Staphylococcus aureus, or MRSA (pronounced Mer-sa) is an important hospital-acquired infection and is a major cause of illness and death resulting in excess of 18,000 US deaths a year and a half million hospitalizations, creating a significant economic burden of approximately $3.4 billion annually to the American health care system.

16 Dec 2009

Advanced Life Sciences Holdings' Restanza promising against tularemia

Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), today announced positive top-line results from a pivotal, non-human primate study of its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin) against an inhaled lethal dose of tularemia. A 14-day course of Restanza achieved a 100% survival rate at the doses tested. All of the ten animals in the study that received 16 mg/kg once-a-day of Restanza (approximate to a human dose of 300 mg) within 24 hours after exposure to a lethal dose of inhaled tularemia survived while only one of the ten animals that received placebo survived.

16 Dec 2009

Majority of workers believe swine flu may impact workflow and productivity

Adecco Group North America's latest American Workplace Insights Survey finds that 77% of workers(1) think their workplace will be impacted in some way by the swine flu.

16 Dec 2009

FDA grants marketing approval for EnzySurge's new SilverStream solution for prescription use

EnzySurge Ltd. (EnzySurge), a provider of innovative solutions for the advanced chronic wound management market, announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its new SilverStream(TM) solution for prescription use. The FDA also cleared DermaSept, an Over-the-Counter version of the SilverStream product.

15 Dec 2009

Advanced Plasma Products launches its new TriClean Pro air sanitizer

Applied Science Products, Inc., announced today that its wholly owned subsidiary, Advanced Plasma Products Inc., has introduced its new TriClean Pro air sanitizer product powered by the company's newest advanced plasma generator design.

15 Dec 2009

Genocea Biosciences to develop Chlamydia trachomatis vaccine with UPMC grant

Genocea Biosciences, a leading vaccine discovery and development company, today announced it has been awarded a grant from the University of Pittsburgh Medical Center’s (UPMC) Sexually Transmitted Infections (STI) Cooperative Research Center for the development of vaccines for Chlamydia trachomatis.

15 Dec 2009

Freie Universität professor receives ERC grant for bacterial biofilm formation study

Prof. Dr. Regine Hengge at the Department of Biology, Chemistry, and Pharmacy at Freie Universität Berlin has been awarded funding from the European Research Council (ERC) for her research project to investigate the formation of bacterial biofilms. Hengge will receive an ERC Advanced Investigator Grant in an amount of up to two million euros.

15 Dec 2009

Optiquant BKV Quantification Panel for MSSA DNA testing procedures

AcroMetrix, a leading provider of quality control standards for clinical diagnostic laboratories, announced today the launch of the first standardized quality control for MSSA molecular testing.

15 Dec 2009

Cubist Pharmaceuticals signs definitive agreement to acquire Calixa Therapeutics

Cubist Pharmaceuticals, Inc. a leading acute care therapeutics company, announced today the signing of a definitive agreement under which Cubist has agreed to acquire privately held Calixa Therapeutics Inc., a biopharmaceutical company focused on the development of novel antibiotics that address the expanding problem of multi-drug resistant Gram-negative pathogens.

14 Dec 2009

Proteins from catfish venom glands could accelerate wound healing in humans

Lest anyone have concerns about attacks of killer catfish, rest assured that, at least in North America, these finned fatales use their venom mainly to defend themselves against predatory fish, though they can inflict a painful sting that many fishermen have suffered. In other parts of the world, some catfish do have extremely toxic venoms that can be deadly to humans.

11 Dec 2009

HSMR helps identify sepsis as an area of concern for Canadian hospitals

A new study shows that in 2008-2009 more than 9,300 patients died of sepsis, a condition resulting from the body's response to severe infection, in Canadian hospitals outside Quebec.

11 Dec 2009

BIOGUARD barrier gauze dressings offer high antiviral efficacy against H1N1

Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a specialty medical device and pharmaceutical company focused on advanced wound care, today released an independent laboratory report indicating that the company's BIOGUARD barrier gauze dressings exhibit high antiviral efficacy against the H1N1 virus.

10 Dec 2009

Bacterial News and Research

PolyMedix completes first two segments of its PMX-30063 antibiotic drug candidate Phase 1B study

Safe living guidelines for transplant recipients

Study explains Salmonella's infection strategy

Cannabis for Ulcerative Colitis and Crohn's Disease treatment

Wood pallet: A source of food poisoning bacteria

New licensing agreement to develop and commercialize prophylactic vaccine against MRSA signed

Survey examines disease R&D investment in 2008

Scientists draw on bacterial decision-making success to guide human choices on H1N1 vaccine

Syntiron grants sanofi pasteur exclusive world-wide license to its human vaccine against MRSA

Advanced Life Sciences Holdings' Restanza promising against tularemia

Majority of workers believe swine flu may impact workflow and productivity

FDA grants marketing approval for EnzySurge's new SilverStream solution for prescription use

Advanced Plasma Products launches its new TriClean Pro air sanitizer

Genocea Biosciences to develop Chlamydia trachomatis vaccine with UPMC grant

Freie Universität professor receives ERC grant for bacterial biofilm formation study

Optiquant BKV Quantification Panel for MSSA DNA testing procedures

Cubist Pharmaceuticals signs definitive agreement to acquire Calixa Therapeutics

Proteins from catfish venom glands could accelerate wound healing in humans

HSMR helps identify sepsis as an area of concern for Canadian hospitals

BIOGUARD barrier gauze dressings offer high antiviral efficacy against H1N1

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News